---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-24-000440"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:22:45.170266+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance

## Summary
- Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
- Core revenue $7.6M (+11% YoY); novel therapies $0.6M (+276% YoY).
- Net loss $1.6M ($0.03 diluted EPS); adjusted EBITDA loss $0.4M.
- Raises FY 2024 revenue guidance to $32.75-33.25M (15-17% growth) from $32.0-32.5M.
- Raises FY 2024 gross margin guidance to 62-63%; year-end cash guidance >$8.8M.

## SEC filing metadata
- accession: 0001161697-24-000440
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169724000440/0001161697-24-000440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169724000440/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-24-000440
- JSON: https://secwatch.observer/filing/0001161697-24-000440.json
- Plain text: https://secwatch.observer/filing/0001161697-24-000440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.